Skip to main content
. Author manuscript; available in PMC: 2018 Jan 22.
Published in final edited form as: Bone Marrow Transplant. 2009 Jul 27;45(3):498–504. doi: 10.1038/bmt.2009.176

Figure 2.

Figure 2

(Left panel) OS by landmark analysis for 291 patients who received chemotherapy alone based on response status at 12 months. The percentages of CR, PR and NR defined at 12 months were 9, 58 and 33%, respectively. Among 25 patients with CR, initial therapy had been dexamethasone (D) in 19, thalidomide-dexamethasone (TD) in 3, and bortezomib-thalidomide-dexamethasone (BTD) in 3; among 170 patients with PR, initial therapy had been D in 154, TD in 11 and BTD in 5. (Right panel) OS of 375 patients who received chemotherapy followed by HDT within 1 year based on response status at 12 months. The percentages of CR, PR and NR defined at 12 months were 27, 64 and 9%, respectively. Among 102 patients in CR, initial therapy had been D in 50, TD in 35 and BTD in 17; among 238 patients with PR, initial therapy had been D in 152, TD in 65 and BTD in 21.